Original Article

Prevalence and Clinical Impact of Atrial Fibrillation in Patients with Pulmonary Embolism

Authors: Yifeng Yang, MD, Baoqiong Liu, MD, PhD, John Taylor, DO, ZhiHua Huang, MD, Sonali Gupta, MD, Soumya Thumma, MD, LingLing Wu, MD, Shuai Wang, MD, George Everett, MD

Abstract

Objectives: Atrial fibrillation (AF) has been suggested as a cause for pulmonary embolism (PE). We aimed to explore the prevalence and clinical impact of AF in patients with PE.

Methods: Using the 2012–2014 National (Nationwide) Inpatient Sample database, we identified “adult patients with PE” as the principal discharge diagnosis. The identified admissions were stratified into two cohorts based on the presence or absence of AF. We used multivariable regression models to evaluate in-hospital mortality, length of stay, nonhome discharge, and in-hospital complications.

Results: The prevalence of AF among the 201,360 patients with PE was 11.62%. Patients with AF were more likely to have massive PE (odds ratio 1.59, 95% confidence interval 1.4–1.81, P < 0.001), with higher mortality (adjusted odds ratio 1.48, 95% confidence interval 1.27–1.71, P < 0.001) and a greater risk of mechanical ventilation, cardiac arrest, and nonhome discharges. The length of hospital stay in patients with PE and comorbid AF was significantly longer than those without (6.24 ± 0.10 vs 4.79 ± 0.03 days).

Conclusions: AF is associated with a higher rate of massive PE, higher in-hospital mortality, a longer length of hospital stay, and a higher incidence of in-hospital complications and nonhome discharge.
Posted in: Miscellaneous Cardiovascular Disease (Physical Examination Findings, Murmurs)2 Miscellaneous Pulmonary Disorders (Indications for Spirometry)2

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Casazza F, Becattini C, Rulli E, et al. Clinical presentation and in-hospital death in acute pulmonary embolism: does cancer matter? Intern Emerg Med 2016;11:817-824.
2. Ng AC, Chung T, Yong AS, et al. Long-term cardiovascular and noncardiovascular mortality of 1023 patients with confirmed acute pulmonary embolism. Circ Cardiovasc Qual Outcomes 2011;4:122-128.
3. Bertoletti L, Quenet S, Laporte S, et al. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res 2013;14:75.
4. Laporte S, Mismetti P, Decousus H, et al. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica Venosa (RIETE) Registry. Circulation 2008;117:1711-1716.
5. Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ 2018;361:k1453.
6. Wang CC, Lin CL, Wang GJ, et al. Atrial fibrillation associated with increased risk of venous thromboembolism. A population-based cohort study. Thromb Haemost 2015;113:185-192.
7. Piszko P, Lewczuk J, Lenartowska L, et al. Pulmonary thromboembolism in 102 consecutive patients with chronic atrial fibrillation. Diagnostic value of echocardiography. Kardiol Pol 2007;65:246-253.
8. Bikdeli B, Abou Ziki MD, Lip GYH. Pulmonary embolism and atrial fibrillation: two sides of the same coin? A systematic review. Semin Thromb Hemost 2017;43:849-863.
9. Barra SN, Paiva LV, Providê R, et al. Atrial fibrillation in acute pulmonary embolism: prognostic considerations. Emerg Med J 2014;31:308-312.
10. Smith SB, Geske JB, Kathuria P, et al. Analysis of national trends in admissions for pulmonary embolism. Chest 2016;150:35-45.
11. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.
12. Otero R, Elias T, Jara L, et al. Factors associated with elevated pulmonary arterial pressure levels on the echocardiographic assessment in patients with prior pulmonary embolism. Thromb Res 2013;131:e191-e195.
13. Piazza G, Goldhaber SZ. Pulmonary embolism in heart failure. Circulation 2008;118:1598-1601.
14. Ko D, Hylek EM. Anticoagulation in the older adult: optimizing benefit and reducing risk. Semin Thromb Hemost 2014;40:688-694.
15. Hald EM, Rinde LB, Lochen ML, et al. Atrial fibrillation and cause-specific risks of pulmonary embolism and ischemic stroke. J Am Heart Assoc 2018;7:e006502.
16. Matthews JC, McLaughlin V. Acute right ventricular failure in the setting of acute pulmonary embolism or chronic pulmonary hypertension: a detailed review of the pathophysiology, diagnosis, and management. Curr Cardiol Rev 2008;4:49-59.
17. Yusuf S, Al-Saady N, Camm AJ. 5-Hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle? J Cardiovasc Electrophysiol 2003;14:209-214.
18. Kukla P, McIntyre WF, Koracevic G, et al. Relation of atrial fibrillation and right-sided cardiac thrombus to outcomes in patients with acute pulmonary embolism. Am J Cardiol 2015;115:825-830.
19. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP). https://www.ahrq.gov/data/hcup/index.html. Published August 2018. Accessed November 25, 2019.